AKRO – akero therapeutics, inc. (US:NASDAQ)

News

Akero Therapeutics to Present at the Jefferies London Healthcare Conference
Akero Therapeutics Advances in MASH Treatment Trials [Yahoo! Finance]
Akero Therapeutics, Inc. (NASDAQ: AKRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com